Marseille, June 4, 2025 – ImCheck Therapeutics today announced its selection to the prestigious French Tech 120 program for the sixth consecutive year, reaffirming its position as a leading French biotech scale-up in immunotherapy.

This recognition highlights ImCheck’s sustained growth and its key role in advancing the goals of France’s Innovation Santé 2030 strategy, which aims to strengthen healthcare sovereignty and position the country as a global leader in innovation.

“We are proud to once again receive this recognition from the French government and its agencies,”said Pierre d’Epenoux, CEO of ImCheck Therapeutics. “Our mission to become a global immunotherapy leader is closely aligned with France’s health innovation ambitions and is further supported by the unprecedented clinical efficacy data in acute myeloid leukemia we presented this week at the 2025 ASCO Annual Meeting in Chicago.”

ImCheck warmly thanks Clara Chappaz, Charles Édouard Escurat, Bruno Bonnell, Nicolas Dufourcq, Éric Lombard, François Bayrou, and President Emmanuel Macron for their continued support of France’s healthtech champions.